2026-04-13T00:58:34Zhttps://recercat.cat/oai/request
oai:recercat.cat:10459.1/4686892025-10-06T18:57:04Zcom_2072_3622col_2072_479130
RECERCAT author Resano-Barrio, Pilar author Gracia-Lavedan, Esther author Solano-Pérez, Esther author García-Mediano, Belén author Cubillos-Zapata, Carolina author Díaz-García, Elena author Romero-Peralta, Sofía author Castillo-García, María author Barbé Illa, Ferran author García-Rio, Francisco author Sánchez-de-la-Torre, Manuel author Mediano, Olga 2025 Introduction In the context of the prevailing interest in biomarkers that can assess cardiovascular (CV) risk in obstructive sleep apnea (OSA), ischemia-modified albumin (IMA) is proposed as a potential risk predictor. Objectives To evaluate whether IMA levels predict recurrent CV events in patients with acute coronary syndrome (ACS) and OSA, and whether continuous positive airway pressure (CPAP) treatment modifies this risk. Methods This post hoc analysis is based on data from the ISAACC study, including 1.011 non-sleepy patients with an ACS. During hospitalization for ACS, a sleep study was conducted and blood samples for IMA determination were obtained. Patients were categorized by their apnea–hypopnea index (AHI) in non-OSA (AHI <15 events/h) or OSA group (AHI ≥15 events/h). “Low” or “high” IMA levels were established based on the median value (⩽ 34.1 U/L or > 34.1 U/L, respectively). The OSA group was randomized to either CPAP or usual care. The recurrence of CV events was evaluated over a 36-months follow-up. Results Adjusted cox regression models showed that the OSA group with high IMA level had a significantly reduced risk for CV event recurrence compared with the non-OSA group (HR [95 % CI] 0.59 [0.38–0.93], p = 0.024). In the OSA group with high IMA level, CPAP treatment did not significantly reduce CV recurrence. Conclusions OSA was associated with higher IMA levels in patients with ACS. Interestingly, patients with both OSA and high IMA experienced fewer CVEs during follow-up. CPAP treatment demonstrated a non-significant risk reduction in patients with low IMA, whereas no effect was noted in those with high IMA. cc-by-nc-nd, (c) Pilar Resano-Barrio et al., 2025 Attribution-NonCommercial-NoDerivatives 4.0 International info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ Obstructive sleep apnea Cardiovascular risk Acute coronary syndrome Biomarkers Ischemia modified albumin Ischemia-modified albumin and cardiovascular risk in obstructive sleep apnea and acute coronary syndrome. Long term follow-up after treatment from the ISAACC study info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion